NCT06199713
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 10 words Show 7 more changesShow less
- Primary endpoints: details revised at 3 of 4 entries
- Enrollment closed, study ongoing
- Enrollment target: estimated 24 to confirmed 25
- Interventions: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (Diagnostic Test) to 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (Diagnostic Test)
- Secondary endpoints: details revised at 7 of 9 entries
- Site details revised
- Study description expanded, about 4 words
- Notable Primary completion date: Jan 2026 to Jan 2027v7
- Notable Eligibility criteria expanded, about 3 wordsv5
- Minor Start date changed from estimate of Feb 2024 to Jan 30, 2024v4
- Minor Start date: Jan 2024 to Feb 2024v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in ctDNA level from baseline to 3-4 week after the start of therapy
Timeframe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Timeframe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Timeframe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
Timeframe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Secondary (9)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
Progression Free Survival (PFS)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
Show 4 moreShow less
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
Overall Survival (OS)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
Arms and interventions
Advanced Melanoma Patients with Immune Checkpoint Inhibitors
Diagnostic tests: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Sites
1 site in 1 country
- University of Wisconsin Hospitals and Clinics (UWHC)Madison, Wisconsin, United States